Sanofi pays $110M upfront for late-stage radioligand therapy, setting up rivalry with Novartis

Sanofi has made a late entry to the radioligand party, paying 100 million euros ($110 million) upfront for global rights to a neuroendocrine tumor treatment that is nearing a filing for approval.